The temporal relationship between primary genital human papiUomavirus (HPV) infections and the induction of antibodies against viral antigens has not been established. In order to address this question we studied a cohort of 110 women and 48 men with multiple heterosexual partners, who were followed for 220 person-years during which they made 583 visits to the sexually transmitted diseases clinic of the Amsterdam Public Health Service. At each visit spatula or brush samples from multiple anogenital and oral sites were collected for HPV DNA analysis by PCR. Serum samples were also collected and analysed for serological reactivity to peptides derived from the L1, L2 and E2 regions of HPV types 6, 16 and 18 as well as to bovine papillomavirus and HPV-16 virus-like particles. Seroconversions for at least three antigens were found among 16/158 patients. Of these, 10/16 were HPV-positive and in 5/16 cases seroconversions occurred concomitantly with the detection ofHPV DNA. Analysis of participants who were HPV-negative at entry, but became HPV DNA-positive during follow-up revealed that antibodies against several HPV antigens were regularly induced at the time of a new HPV infection, in particular the IgG responses against HPV-16 virus-like particles and against the HPV-16 E2-derived peptide 245. Whereas the responses induced among the women with new HPV-16 infection tended to continuously increase, the responses among the men with any type of new HPV infection were mostly transient and disappeared during follow-up. In conclusion, we find that antibody responses to multiple viral antigens are often induced following the detection of genital HPV infection, that the type-specificity of the response is limited and that transient responses are common.
Introduction
In total 68 human papillomavirus (HPV) types have been detected, of which 27 are associated with lesions of the oral and anogenital mucosal epithelium (de Villiers, 1992) . Those with tropism for the mucosa are subdivided into two groups, the first consisting of'low risk' HPV types (e.g. HPV-6, HPV-11), which primarily induce benign anogenital warts (condylomata acuminata) and the second group consisting of the 'high risk' types, which can cause anogenital intraepithelial neoplasia (Schiffman et al., 1993) and progress to anogenital cancer, in particular cervical cancer. Studies on the natural history of HPV infection have indicated that a high proportion of cervical HPV-associated lesions regress spontaneously (Syrj~inen & Syrjfinen, 1990) . Longitudinal studies, based on DNA analysis of repeated samples from sexually active patient groups, have * Author for correspondence. Fax +46 8 326702. e-mail Joakim, DiUner@mtc. ki. se suggested that a high proportion of infections are transient, i.e. DNA of a specific HPV type is frequently only detected on a single occasion (van Doornum et al., 1992; Rosenfeld et al., 1992) . Several epitopes reactive with antibodies preferentially found in sera of patients with cervical intraepithelial neoplasia (CIN) or cervical cancer have been defined for the E2, E6, E7 and L1 proteins ofHPV-16 (J. Dillner et al., 1989 Dillner et al., , 1990 Dillner et al., , 1994 J. Dillner, 1990; Mueller et al., 1992; Krchfi~ik et al., 1990) . Several studies using fusion protein immunoblotting were not able to find disease-specific antibodies (Jenison et al., 1990) presumably because several HPV proteins contain epitopes broadly cross-reactive among HPV types (L. Dillner et al., 1991) . However, HPV-16 viruslike particles (VLPs) have recently been produced in a baculovirus expression system (Kirnbauer et al., 1993) . Antibodies to these particles have been detected in 59 % of women positive by PCR for HPV-16, as compared to 6 % of HPV-negative controls (Kirnbauer et al., 1994) .
The kinetics of the antibody response against genital HPV types is not known. A. Wikstrgm and others associated lesions such as CIN or cervical cancer, it is not known whether HPV antibody responses are detectable following primary HPV infection. In the present study we used a panel of peptide-defined epitopes as well as HPV-16 VLPs to measure the development of HPV serological responses over time in a cohort of sexually active men and women periodically monitored for genital-type HPV infections.
Methods
Patients. Between May 1988 and December 1990, the participants of this study were recruited among visitors attending the sexually transmitted diseases clinic of the Municipal Health Service of Amsterdam who had entered into a study on the heterosexual spread of human immunodeficiency virus (HIV). Inclusion criteria were: age of 18 years or older and sexual contact with five or more heterosexual partners within six months before entry. Exclusion criteria were: haemophilia, homosexual contacts or intravenous drug use in the preceding 5 years (Hooykaas et al., 1989; van der Linden et al., 1990) . Visitors willing to comply with follow-up visits every 4 months and to provide written informed consent were asked to enter the HIV study. At each visit, physical examination was performed and a standardized questionnaire was completed. At one of the follow-up visits, participants were asked to enter the HPV study. Of the 354 women and 267 men who entered the HIV study, 162 women and 85 men consented to be enrolled into the HPV study. Of these, 110 women and 48 men could be followed until January 1992. These patients were included in this study (for a further description of the cohort, see van Doornum et al., 1992) .
Each patient visited the clinic on two to seven occasions (mean 3.7); 43 patients had visited the clinic twice, while 33, 37, 25, 15 and five patients had visited the clinic three, four, five, six and seven times, respectively. At each visit, specimens were taken for HPV DNA detection with the PCR assay, using type-specific primers for HPV-6/11, -16, -18 and -33 as described (van Doornum et al., 1992) . Samples from the males were taken from the mouth, anus, rectum, coronal sulcus and urethra. From females, specimens were analogously taken from the mouth, anus, rectum, cervix and from the labia minora. Serum samples were also taken at each visit. Cytological smears were taken at each visit but only 3/110 women were found to have atypical cells.
The 110 women (mean age = 31 years) were followed over a period of 155.14 person-years (411 visits). For women, the mean duration of the follow-up period was 513 days (SD = 256, and the mean interval between the visits 188 days (SD = 96, range = 72-672). The 48 men (mean age = 37 years) were followed over a period of 65-4 person-years with a total number of 172 visits. The mean duration of the follow-up was 498 days (so = 269, range = 119-902) with a mean interval of 193 days (SO = 110, range = 75 679) between the visits.
ELISA methodology. A panel of eight HPV-derived peptides, the sequences of which are listed elsewhere (J. Dillner et al., 1994) , were synthesized as peptide amides using tBoc chemistry, as described (J. Dillner, 1990; . The peptides had previously been extensively characterized for serological reactivity (J. . HPV,16 VLPs were purified from recombinant baculovirus-infected insect cells by CsC1 gradient centrifugation as previously described (Kirnbauer et al., 1993) . Bovine papillomavirus (BPV) from two strains (B20 and B37) was similarily purified.
The ELISA was performed as described (J. Dillner et al., 1994) . Briefly, the synthetic peptides were coated onto ELISA plates at 20 lag/ml in 0.1 M-Tris HC1 pH 8.8, HPV-16 VLPs at 1 lag/ml in PBS and BPV at 20 lag/ml in 0.1 M-carbonate buffer pH 9.6. Human sera were tested at a 1 : 30 dilution, or 1 : 100 in the case of BPV. Human sera were diluted in 10% horse serum in PBS, or for BPV assays in 10% lamb serum in PBS. Bound antibodies were detected with monoclonal antibodies to human IgA, IgG or IgM (Eurodiagnostics) and a horseradish peroxidase-conjugated antibody to mouse IgG (Southern BioTechnology). For each serum the difference in A~0 ~ (dA) was calculated by subtracting the absorbance obtained in wells coated only with buffer from the absorbances obtained in antigen-coated wells.
The ELISA results are presented as an increase (+) if antibody responses increased in A~o ~ by at least 0.100 between the first and last visit and a decrease (-) if they decreased by 0" 1 O0 between the first and last visit. They are described as transient increases or peaks (P +) if the values increased and then decreased to levels close to values at the first visit. Conversely, an inverted peak (P-) is defined as a U-shaped curve with a transient decrease of titres. No change in the ELISA assay is defined as '0' (increase/decrease < Aa0 ~ 0.100 or no reaction at all).
Results
The first and last serum samples from all patients were analysed by ELISA using a panel of five HPV-16-derived peptides (Ll:13, Ll:31, L2:49, 245:16, E2:9), one Table 2 . Mean titres for patients that seroconverted and one HPV-6-derived peptide (245: 6) as well as denatured BPV virions and HPV-16 VLPs. One HPV-16-derived peptide (E7: 5) was only tested on 110 patients (data not shown). Of the 158 patients tested, 16 demonstrated seroconversions for at least three assays (defined as a first visit serum sample with ELISA dA < 0.100 and a last visit serum sample with ELISA dA > 0-200). We analysed the serum samples from all visits (Table 1) for these patients.
Patients showing seroconversion
Seroconversions in three assays were noted among seven patients and seroconversions in four, five, six and seven assays were found among two, two, four and one person, respectively (Table 1) . Total follow-up time was 23 person-years (45 visits) with a mean duration of followup of 519 days (range 117-1233) and a mean interval between the visits of 183 days (range 99-393).
Out of 16, 10 (62%) of the patients were HPV DNApositive at one or more occasion in the PCR assay (Table  1) . Among the 10 seroconverters positive for HPV DNA in the PCR assay, we also compared at which visit the HPV DNA was detected with the visit when seroconversion occurred, as indicated by the maximum at the second visit whereas the samples from all other sites and at all other visits were negative. There were 852 days between the first and the last visit. The responses for all Ig classes (IgA, []--; IgG, --0--; IgM, --Ira--) came at the same time and were already present at the second visit for L1:31 (a), L2:49 (b) and Ll:13 (data not shown). The IgA and IgM against these antigens disappeared quickly after clearance of infection whereas IgG against Ll:31 and Ll:13 persisted For HPV-16 capsids, 245:6 and 245:18 there was a seroconversion at the third visit (Table 1) .
ELISA titre. For five patients, the HPV DNA was found at the same visit as the antibody peak. For three patients the HPV DNA was found at the visit before the peak, and for one patient the HPV DNA was found in the visit after the peak. For one patient the titres against the various antigens were irregular to the extent that the position of a single peak could not be determined. For the other patients it was, however, obvious that the seroconversions against the different antigens had occurred at the same time. For the five patients with only two visits (Table 1) , it is trivial that seroconversion had occurred at the second visit. For the remaining 11 patients, the seroconversion had occurred at the same time for the different antigens in 34/43 cases. In contrast, the expected number of seroconversions at the same time in case of a random distribution is 13/43 (p < 0.0001) ( Table 1) .
As shown in Table 2 , there is a large increase in ELISA titres during follow-up for most of the antigens studied. The difference between minimum and maximum titres was always positive (i.e. increase during follow-up) and exceeded 1.0 for several antigens, in particular for IgG. The amplitudes of the ELISA titres vary between the different assays (Table 2 ). This reflects partly the relative abundance of these antibodies in the sera. In the case of denatured BPV virions and native HPV-16 VLPs, the HPV-16 was used at a much lower concentration of antigen (50 ng/well as compared to 1 gg/well for BPV). At 1 gg/wei1 the serologic reactivity of disrupted HPV-16 resembles that of disrupted BPV, and the HPV-16 coating concentration was therefore diluted to the point where very little group-specific reactivity was seen. The 'HPV-16 disrupted' assays (using 50 ng/well) are included as a negative control for the 'HPV-16 intact' assay (Table 2) . In most cases, the seroconversion occurred at the same visit for both IgA, IgG and IgM. For some antigens (e.g. 245: 18) the IgA response was slower (peak after 18 months of follow-up) than the IgM response (peak after 5.5 months of follow-up) ( Table 2) .
In Table 3 , the shapes of the ELISA curves among the seroconverters for the various antigens are categorized as + (continuous increase), -(continuous decrease), P (peak), P-(inverted peak) or no change (0). In all 27 assays there were patients who had increases in ELISA titres, but decreases were seen in only five assays. In 13 assays positive peaks were present and in three assays there were inverted peaks. In 26% of assays no seroreactivity or no change in titres was seen.
The kinetics of antibody induction differed for each antigen. The development of antibody responses over time is summarized below for each antigen.
L1 ." 13
Peptide L1 : 13 is derived from the internal region of L1 of HPV-16 and antibodies against this peptide associate with cervical cancer (J. Dillner et al., 1990 Dillner et al., , 1994 . The antibody response for this peptide was somewhat slow. IgA and IgM antibody responses came concurrently for 4/8 patients. The IgM titres were qmte low (dA < 1-0) in (Fig. 1 a) . the response for IgM was highest for all of the nine patients (dA > 1.0 for 6/9) and the IgG titres were usually low (dA > 1.0 for only one patient). The response was slow and gradual.
245:16

245:18
Peptide 245:18 is derived from the homologous E2 region of HPV-18 (Lehtinen et al., 1992) and antibodies against this antigen are preferentially found in cervical cancer. It shows no detectable cross-reaction with the 245: 16 and 245 : 6 peptides and the titres do not correlate (J. Dillner et al., 1994) . The titres of all antibody classes IgA, IgG and IgM started to rise at the same time for all patients.
E2:9
This antigen is derived from an internal E2 region and elevated titres have been found among patients with cervical or anal cancer (J. . The titres for IgA and IgG were low, compared with the IgM response to this peptide, for 3/6 patients (dA < 0.3 for these three patients for both IgA and IgG). In comparison to IgA and IgG, higher titres were measured for IgM for these three patients (dA > 0"5 for two patients).
L2 ." 49
This peptide is derived from the middle of the L20RF ofHPV-16 (J. Dillner et al., 1990) . For this antigen, there was a remarkably low IgM reactivity (dA < 0"5 in 8/9). The IgG titres were highest in 7/9 cases (dA > 1.0 in 5/9) and IgA somewhere in between. See example for patient number 158 (Fig. 1 b) .
BPV
Antibodies against BPV were measured using purified, carbonate buffer-disrupted BPV particles from two viral strains (number B20 and B37). The response to this antigen generally came relatively rapidly. Among sera from eight of the 11 patients analysed for this peptide, the IgA response was lower than the IgG and IgM responses. However, in three cases the IgA response was not the lowest. The IgG and the lgM responses were detected at the same time for four of the patients, whereas the IgA and the IgM responses followed one another in four of the patients.
HPV-16 virus-like particles
Reactivity to intact HPV-16 VLPs was analysed for 15 of the seroconverters. The titres were highest for IgM in 11/15 patients, for IgG in 3/15 patients and for IgA in one patient. For 14/15 patients, the amplitude was lowest for IgA. For 12/15 patients the response also came faster for IgM than for IgA and IgG.
Men with newly detected HPV DNA
Using the PCR assay, a total of 87/158 patients were positive for HPV DNA on one or more occasions for one or more HPV types. Fluctuating infections, i.e. the same HPV type present at the same location with a negative result for HPV DNA at visit(s) in between, were only detected in 6/87 (7 %) cases. HPV DNA was detected at one or more visits during follow-up in 49 patients (14 men and 35 women) who were HPV DNA-negative at enrolment. Of these, all 14 men with newly detected HPV DNA and 10 women with newly detected HPV-16 were selected for further analysis.
Of the 14 men with newly detected HPV DNA, HPV-6/11 was found in six patients. HPV-16, -18 and -33 were found in five, seven and two men, respectively. Five men acquired more than one HPV type. Of these 14 men, two were analysed among the group of seroconverters (patients 158 and 304). The results of the analysis of the remaining 12 men are presented in Tables 4 and 5 .
The antibody responses were determined for the L l : 13, L 1 : 31, L2: 49, 245: 6, 245: 16 and 245: 18 peptides and against HPV-16 intact capsids (with disrupted capsids as control). The development of antibody levels over time was measured as the difference between lowest and highest antibody levels. In case of decreasing titres during follow-up, the difference between lowest and highest values was recorded as negative. In case of random fluctuation of titres, the expected mean difference is thus zero. However, in 20/21 assays the mean difference was positive (Table 4) , in some cases with a mean increase in dA of more than 0.6, indicating that new HPV DNA detectability regularly induced a titre increase against the studied antigens. This regular increase is even somewhat underestimated in Table 4 , since the two men with new HPV DNA infection who were scored as seroconverters are not included. Most of the antibody responses studied showed a change in titre during follow-up for these men. The shapes of the ELISA curves are classified in Table 5 . The most common type of response was the transient peak, which was seen in 27 % of all assays. This is exemplified in Fig.  2 b, which displays the IgG anti-HPV-16 capsid responses for the 7/12 men where changes in dA > 0-100 were recorded.
Women with new HPV-16 infection
Altogether, 17 women were found who were HPV DNAnegative at the first visit, but became positive for HPV-16 during follow-up. Of these, 10 women with more than two visits were selected for further analysis. All of the women were analysed for antibody reactivity to peptides Ll:13, Ll:31, 245:16, (Table 6 ). The most common response was a continuous increase, +, seen in 28% of the assays, whereas 13 %, 13% and 3% were described as -, P and P-, respectively. In Fig. 2 , development of antibodies over time in relation to HPV DNA detection is shown with IgG to HPV-16 capsids and IgG to 245: 16. On an individual level, continuous increase was the most common pattern of change for 6/10 patients (Table 7) . Two aberrant patients showed the opposite pattern, with most responses decreasing during follow-up.
Discussion
Most studies of the antibody response against genital HPVs have used a cross-sectional format, which does not permit analysis of the development of antibody responses over time. In longitudinal studies of patients with cutaneous warts, it was found that the antibody response was slow, sometimes taking many months to develop after the onset of warts (Cubic, 1972) . Longitudinal studies of genital HPV infection or genital HPVassociated lesions are difficult to perform since the infection and associated cervical lesions are usually asymptomatic and the time of onset is uncertain. In follow-up studies of patients with cervical koilocytic atypia, the IgA response has been found to wane after spontaneous regression of lesions (Lehtinen et al., 1990 (Lehtinen et al., , 1993 . The present study has not targeted patients with HPV-associated lesions but rather patients with asymptomatic HPV infection where the infection appears to be cured before development of disease: in the vast majority of cases, HPV DNA detectability had disappeared between one visit and the next and very few cytologic abnormalities were found.
Our findings that new HPV DNA detectability is accompanied by a concomitant increase in HPV antibody titres suggest that the primary antibody response against genital HPV is faster than would have been expected by analogy with the slow development of antibodies in the cutaneous wart system. However, since the mean interval between two visits was 6 months, we can only conclude that an antibody response does develop within this time interval after infection. The titres against all antigens usually increase when HPV DNA is detected (or somewhat afterwards); the shapes of the curves are, however, different for the different antigens. Since the intervals between the visits and the number of visits made by each patient vary, the ELISA curves are not directly comparable between the patients. Also, we do not know if the kinetics of the antibody response may differ between patients with asymptomatic infection, as in this study, and patients with HPV-associated lesions. Many of the HPV antibody responses, especially IgA and lgM, were transient and reached a maximum titre within 9 18 months. As detailed in the Tables, many were transient to the extent that the antibody titres returned to levels as low as before the infection was detected by DNA analysis, the serological response pattern that we designated as a 'peak'.
In the present study of 158 people with multiple sexual partners, HPV DNA was found at least once at some site in 87/158 (55%) of patients. Although samples were taken from five locations in both men and women, infections at sites not being sampled would have escaped detection. Also, we only performed PCR with typespecific primers for HPV-6/ll, -16, -18 and -33, and would therefore not have detected infections with other genital HPV types. This could account for the seroconversion to multiple HPV antigens seen in several HPV DNA-negative patients, it also appears likely that a large proportion of subjects in the cohort would have been exposed to genital HPV already before entry into the study. That seronegative individuals, seroconversions
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and titre increases following infection could nevertheless be found is probably due to the transient nature of many of the HPV antibody responses. Some of the newly detected infections might actually be due to established infection, where the HPV DNA detectability is fluctuating (reactivation of latent infection). However, fluctuating HPV DNA positivity for the same HPV type on the same location was only found in 6/87 (7 %) of the HPVpositive patients. Also, even if some of the cases of new HPV DNA detectability are not new infections, but rather reactivation of pre-existing infection, it is quite conceivable that such reactivation might also cause induction of increased HPV antibody titres.
The identification of HPV seroconversions also contributes to the evaluation of HPV serological assays. In the absence of a defined control population unexposed to HPV, serological assays have had to rely on alternative specificity criteria. Certain HPV serological assays have relied solely on the questionable specificity criterion that their antigenic reactivity was found in some HPVderived fusion proteins but not in others (Yaegashi et al., 1992) . The specificity criteria of the HPV serological assays used in this study are that antibodies are preferentially found among patients with HPVassociated diseases (245: 16, 245: 18, 245:6, LI: 13, E2:9 and HPV-16 VLPs; J. Dillner et al., 1989; Lehtinen et al., 1990 Lehtinen et al., , 1992 Reeves et al., 1990; Wikstr6m et al., 1992) , that seropositivity against several HPV-derived antigens is found in the same patients (e.g. for L1:13, L 1 : 31 and L2: 49; J. or that antibody titres decrease following treatment or spontaneous regression of HPV-associated lesions (J. Lehtinen et al., 1990) . In the present study, the fact that seroconversions against multiple HPVderived antigens occurred at the same time strongly indicates that the antibodies were induced by the same infection.
HPV type-specificity does, however, appear to be limited for all the analysed antigens, since induction of antibodies was in no case restricted to infections by a certain HPV type, For example, among the seroconverters, all of the patients tested for serological reactivity with denatured BPV virions were positive for IgG and IgM, in line with the broad cross-reactivity of this antigen. A higher amplitude of the titres (mean maximum dA: 0.712 versus 0"337) and more common continuous increase for IgG to HPV-16 VLPs among the women with new HPV-16 infection compared to the men with new infection (any type), who mostly had transient responses, suggests that this antigen is at least partially type-specific, being induced at higher levels and tending to prevail when infection with HPV-16 itself occurs.
In summary, the present study has shown that antibody responses can be induced following HPV infection, but that many responses are transient and have limited type-specificity.
